SOPHiA GENETICS SA
SOPHHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeSOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. At a $711.7M market cap, SOPHiA GENETICS SA ranks as a small-cap company within healthcare. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Market Cap
$711.7M
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-16.72
EPS (TTM)
$-1.16
EPS (Fwd)
$-0.50
ROE
-101.2%
ROA
-24.5%
Cash
$107.7M
Total Debt
$61.8M
Free CF
-$25.7M
52W Change
148.2%
Annual Financials
Cash vs Debt
Where SOPH stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SOPH finished 50.55% above its 150-day moving average ($5.50) and 55.35% above its 200-day moving average ($5.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SOPH overbought or oversold?
At the September 3, 2026 close, SOPH's RSI(14) was 59.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $107.7M in cash comfortably exceeding the $61.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$25.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -101.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $40.5M (2021) to $77.3M (2025), reflecting a 91% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence SOPHiA GENETICS SA's trajectory.